An announcement from BioVie ( (BIVI) ) is now available.
BioVie Inc. announced the successful closing of its registered direct offering, raising $3.24 million by selling 1,146,000 shares of its common stock at $2.83 per share. The funds will primarily be used for working capital and corporate purposes. As a clinical-stage company, BioVie is developing innovative therapies for chronic conditions like liver disease and neurodegenerative disorders, with promising drug candidates in the pipeline.
For an in-depth examination of BIVI stock, go to TipRanks’ Stock Analysis page.
